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Summary 
We investigated mechanistic differences in antigen presentation between murine MHC  class  I 
variants H-2K  b and H-2K  bm8. H-2K  bin8 differs from H-2K  b by four residues at the floor of the 
peptide-binding  site, affecting its B  pocket which interacts with the second (P2) residue of the 
peptide.  The rest of the molecule, including the T  cell receptor (TCR)-contacting  residues, is 
identical to H-2K  b. Due to this variation,  CTLs that recognize the ovalbumin257_264 and HSV 
gB498_505 peptides  on H-2K  b cannot  recognize  them on  H-2K  bros. This  could be due  to im- 
paired peptide binding or an altered peptide:K  bin8 conformation.  Peptide binding studies ruled 
out the first explanation￿9 Molecular modehng indicated that the most obvious consequence  of 
amino acid variation between peptide/H-2K b and peptide/H-2K bms complexes would be a loss 
of the conserved hydrogen bond network in the B  pocket of the latter.  This could cause con- 
formational variation of bound peptides.  Intermolecular second-site reversion was used to test 
this  hypothesis:  P2-substituted  OVA  and  HSV peptides,  engineered  to  restore  the  hydrogen 
bond network of the B pocket, were the only ones which restored CTL recognition.  These re- 
sults provide a molecular understanding  of peptide/MHC  conformational variation. 
M 
HC class I molecules are the most polymorphic mol- 
ecules  in  mammals  (1).  This polymorphism  can in- 
fluence  T  cell recognition  by:  (a)  changing the  class  I sur- 
face that directly interacts with the TCtL; (b) changing a set 
ofpeptides that can be presented to the TCR.; and (c) bind- 
ing the same peptide(s)  in a different conformation.  While 
the  first  two  mechanisms  are  well  understood  (2-4),  the 
third  one  is still obscure.  In theory,  conformational varia- 
tion  could  work  as  follows:  MHC  alleles  X  and  Y  differ 
from each other only at peptide-binding  residues, and both 
can bind peptide A. As a consequence  of differential inter- 
actions  in  the  peptide-binding  site,  A/X  and  A/Y  would 
structurally  differ from each  other.  Some  of this  variation 
may be  accessible  to the  TCR,  and  TCRs  that recognize 
A/X  may  not  be  able  to  recognize  A/Y.  Studies  using 
MHC  or peptide variants invoked conformational variation 
as a cause for altered T  cell recognition  whenever peptide: 
MHC  binding appeared to be intact (reviewed in reference 
A partial and preliminary account of this work was presented at the 1993 
Keystone Symposium, Taos, NM. 
5). One study implicated conformational variation as a ma- 
jor  cause  for  alloreactivity  (6):  the  same  HPLC  fraction 
eluted  from  H-2K  bm8  and  H-2K  b  molecules,  presumably 
containing a shared selfpeptide(s),  was differentially recog- 
nized  by  CTLs  when  bound  to  H-2K  b versus  H-2K  bros. 
However,  neither  of the  above studies  employed methods 
that could reveal the structural mechanism of variation. To 
address this  issue,  we used chemically,  and,  in some cases, 
crystallographically,  defined  peptides  and  natural  MHC 
class  I  variants,  and  the  technique  of intermolecular  sec- 
ond-site reversion. 
Materials and Methods 
Mice, Immunization and SlCr-release Assay.  C57BL/6 (B6, H-2  b) 
and B6.C-H-2 bins (bm8,  H-2  bn~s) mice were  obtained from the 
NCI (Frederick, MD) and Dr. J. Sprent (The Scripps Institute, La 
Jolla, CA), respectively. The latter were bred at the MSKCC vi- 
varium. Peptide and virus immunization, restimulation, and 51Cr- 
release assay were performed exactly as described (7). 
Peptides and the Peptide:MHC Binding Assay.  Peptide-MHC 
binding was quantified by determining relative expression of sta- 
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lines in the presence of indicated peptides  (8). The peptides  OVA 
(SIINFEKL), O2E (SEINFEKL), O2A (SAINFEKL), O2D (SDIN- 
FEKL),  HSV (SSIEFARs  H2E  (SEIEFARL), and HIV (R.G- 
PGRAFVTI) were f-moc-synthesized, and HPLC purified to >95% 
purity (MSKCC Microchemistry Core Facility). The RMA-S cell  Immu- 
line and its H-2Kb-loss variant  (a gift of Drs. J. Rogers and R.P,.  Strain  nization 
Rich,  Baylor  University,  Houston,  TX)  transfected  with  the 
H-2K  bin8 cDNA (from Dr. L. Pease, Mayo Clinic, Rochester, MN)  B6  OVA 
were used for the assays, which were performed exactly as previ- 
ously described  (8). % maximal stabilization was calculated relative 
to the levels of total  (empty and peptide-associated)  H-2K  b and 
H-2K  bins at 29~  as: (MFI with peptide at 37~  -  MFI without 
peptide at 37~  at 29~  -  MFI without peptide at 37~ 
￿  100, where MFI =  mean fluorescence intensity.  Results  were 
corroborated using competitive inhibition of CTL lysis. 
Computer Modeling of the Peptide:MHC Complexes.  Figures were 
generated using RIBBONS (9). All three models (Fig. 2, b-d) were 
generated by TOM (10), based on the crystal structure of OVA/  B6  HSV 
K b (11) (Fig.  2  a),  using preferred  side  chain rotamers.  Energy 
minimization studies,  performed using Biosym (San Diego, CA) 
software,  indicated that the models were energetically  favorable. 
Table 1.  Second-site  Reversion of the H-2K  bm8 Presentation Defect 
by Substituted Peptides 
% 51Cr-release (-log M 
peptide concentration) 
Targets  6  8  10  12 
Kb/OVA  77  70  79  55 
Kb/O2E  6  4  4  7 
Kb/O2A  71  75  50  40 
Kb/O2D  4  3  1  0 
KbmS/OVA  0  0  0  0 
KBmS/O2E  42  28  3  0 
KbmS/O2A  11  0  0  0 
KbmS/O2D  7  2  0  0 
Kb/HSV  71  70  46  16 
Kb/H2E  8  5  2  1 
KbmS/HSV  1  0  -  l  0 
KbmS/H2E  42  40  17  2 
Results and Discussion 
T Cell Recognition of HSVand OVA Peptides Complexed to 
K b and K bms.  When immunized with intracellularly loaded 
ovalbumin or live virus,  or with  OVA or HSV glycopro- 
tein B498_505 peptides,  B6 mice mount CTL responses  di- 
rected against naturally processed epitopes SIINFEKL (OVA) 
and SSIEFARL (HSV),  presented  by H-2K  b (7,  Table  1). 
These  two  peptides  share  the  same  principal  anchor resi- 
dues, in positions five and eight (P5F and P8L), and a me- 
dium-size  residue  at P2  (I and  S,  respectively).  P5F and a 
medium-size  residue  at  P2  (in  contrast  to  tyrosine  [P5Y] 
and  a  small  P2  residue  in  H-2Kb-binding  peptides  VSV 
[RGYVYQGL] and SEV [FAPGNYPAL]) characterize the 
"OVA" submotifofH-2Kb-binding peptides (11). Peptides 
with this submotif contact the central H-2K  b pocket C  by 
P5F,  but,  unlike  the  VSV and SEV peptides,  also interact 
with pocket B via P2 (11-13).  This interaction has the po- 
tential to affect T  cell recognition (14,  15). 
B6 anti-OVA CTLs cannot recognize OVA when pre- 
sented by H-2K  bin8 (5,  16, 17, Table 1). HSV, another pep- 
tide with the "OVA" submotif, also failed to be recognized 
when  presented  by  H-2K  bin8  (Table  1).  H-2K  bin8 differs 
from  H-2K  b  by  three  [~-strand  substitutions,  Y22---)F, 
M23--+I,  and  E24---~S,  and  a  loop  substitution  A30-+N 
(18), all located on the floor of the peptide binding site (11, 
19).  Crystal structure analysis (11, 20) and site-directed mu- 
tagenesis  (21,  22)  have shown that the  mutations  Y22-+F 
and E24-+S occur in the pocket B  of the peptide binding 
groove, where they may directly affect peptide binding, but 
have no solvent accessibility and thus  are predicted  not to 
interact  directly with the  TCR.  Residues  23  and 30 point 
away from the peptide binding groove and are functionally 
irrelevant  for peptide  binding  and  TCR.  recognition  (12, 
20, 21). 
Impaired  Peptide  Binding Does  Not Account for  the Lack 
of OVA/K  ~ms and HSV/K  bins Recognition.  The  inability  of 
CTLs were derived by peptide immunization (7). 51Cr-release assays 
were performed on peptide-pulsed S.B6 (H-2K  b) or S.bm8 (H-2K  bms) 
(16) target cells. The assays were performed in triplicates (absolute vari- 
ation: -+3% 5lCr release) at a 10:1 E:T ratio. % specific lysis was cor- 
rected for the lysis ofunpulsed target cells (<5%). Results are represen- 
tative of >20 experiments. 
H-2K  bm8 to present OVA and HSV could be explained by: 
(a) significant H-2Kbm8-induced, peptide-independent,  struc- 
tural changes that alter TCR  contact;  (b)  impaired peptide 
binding;  or  (c)  subtle,  peptide-dependent  local  conforma- 
tional variation of the peptide/MHC  complex. H-2K  b and 
H-2K  bms are indistinguishable as assayed by a panel of con- 
formation-sensitive  mAb,  directed  against  the  Ix-helical 
regions  of the  Ixl  and  Ix2 domains  (5,  16).  Furthermore, 
H-2K  bin8 can  present  other  peptides  (e.g.,  the  VSV  and 
SEV peptide)  to B6 CTLs (10, R. Dyall, unpublished data). 
These findings argue strongly against the first possibility. 
Binding  of  OVA  and  HSV  peptides  to  H-2K  b  and 
H-2K  bm8 was tested using a class I-stabilization assay (8,  Fig. 
1).  Identical results were obtained using a modified stabili- 
zation assay (not shown),  that took into account the  pep- 
tide off-rates (by thoroughly washing the peptide away be- 
fore a 4-h incubation at 37~  The results were, therefore, 
representative  of the  binding  capacity  of peptides  tested. 
HSV bound equally well to H-2K  b and H-2K  bin8 (Fig.  1,  a 
and b).  OVA did not bind to H-2K  bins as well as to H-2K  b 
(Fig.  1,  c and  d).  However,  impaired  binding alone  could 
not  explain  the  lack  of OVA/K  bin8 recognition,  because 
even at the  OVA concentration which produced substan- 
tial H-2K  bm8 stabilization  (10 -6 M, Fig.  1 d), there was still 
no  recognition  of this  complex  (Table  1).  These  results, 
therefore, rule out the second explanation. 
Could a local structural variation explain  the phenotype 
of H-2Kbm8?  Crystal  structures  of H-2K  b  complexed  to 
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Figure  1.  Peptide binding to H-2K  b and 
H-2K  bros. (a and b) Binding of HSV (squares) 
and H2E (drdes) to H-2K  b (a) and H-2K  bins 
(b). HIV (triangles) is a control Dd-binding 
peptide;  (c and d), binding of OVA (filled 
squares) and its variants, O2E  (filled circles), 
02A (open circles), O2D (open  squares) and HIV 
(filled triangles) to H-2K  b (c) and H-2K  bms 
(d). Peptide-MHC  binding was quantified 
as described in (8). Comparable results were 
obtained in three other experiments. 
OVA (Fig. 2 a, reference 11), VSV and SEV (12) show that 
all three complexes share a conserved hydrogen bond net- 
work in  the B  pocket,  and the  HSV/K  b complex is likely 
to  preserve  it  (Fig.  2  b).  The  substitutions  Y22--)F  and 
E24---)S in  H-2K  bins would  be predicted  to alter the  con- 
served  hydrogen  bonding  network  (see  a  naive  model  of 
KbmS-HSV,  Fig.  2  c).  We  conclude  that  OVA/H-2K bm8 
and HSV/H-2K bin8 complexes are unlikely  to be isostruc- 
tural with their H-2K  b counterparts. By methocl~ employed 
here,  it is not possible to determine  which peptide and/or 
MHC  residues  would  move.  However,  likely  candidates 
for  this  predicted  structural  variation  include  the  TCR.- 
accessible  backbone  atoms  of peptide  residues  P1-P4,  as 
well as TC1L-accessible MHC  residues K66 and N70 which 
sit atop the B pocket. 
Intermolecular  Second-site  Reversion  Restores  CTL  Recogni- 
tion and Provides Evidence for Conformationat  Variation.  A  spe- 
cific prediction  of this  model is that  the  reconstitution  of 
the  hydrogen  bond  network  in  the  B  pocket  may restore 
TCR  recognition  of peptide/K bms. To test this prediction, 
we  adapted  a  genetic  technique  of second-site  reversion 
(23,  24),  whereby protein  (usually enzyme) point-mutants 
are functionally rescued by spontaneous mutations at a dis- 
tant  (second)  site,  providing  information  on  functionally 
important intramolecular interactions.  We used substituted 
peptide  as  an  intermolecular  second  site.  If we were  cor- 
rect,  re-introduction  of a  peptide  side  chain  of medium 
size,  which  could  participate  in  the  B  pocket  hydrogen 
bonding  network,  might  restore  the  recognition  of pep- 
tide/K  bm8  complexes.  Of  several  substituted  OVA  and 
HSV peptides,  those bearing glutamic acid at P2 (O2E and 
H2E)  were  recognized  by B6  CTLs  (Table  1,  Fig.  3,  and 
not shown).  The second-site  effect depended  on the posi- 
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tion,  the size and the nature  of peptide substitution.  Other 
P2 variants,  with  smaller acidic  (O2D)  or medium  (OVA 
wt,  H2I)  or  small  (O2A)  hydrophobic  side  chains,  or  a 
small hydrophilic  side chain which  could not form hydro- 
gen  bonds  with  MHC  side  chains  in  the B  pocket  (O2S) 
could not rescue recognition  (Table 1; not shown). It could 
be  argued  that  the  second-site  reversion  may  not  strictly 
depend on the B pocket hydrogen bond network,  and that 
it could be achieved by other substitutions in the peptide as 
well. We did not test all possible peptide variants, and thus 
cannot formally exclude this possibility. However, we con- 
sider  it  highly  unlikely,  for two  reasons.  First,  neither  of 
several TCk-exposed  or buried substitutions  tested (O4R, 
O2E4E,  O7E,  O7Q,  O4E,  O5Y,  H5Y,  and  H7K)  could 
restore  recognition  (not  shown).  Second,  OVA  peptides 
substituted  at all buried or all exposed residues with amino 
acids from the VSV peptide (SGYNYEKL and RIIVFQGL, 
respectively) also failed to restore recognition  (not shown). 
These  results  strengthen  the  conclusion  that  the  original 
K bin8  mutation  and  the  second-site  peptide  substitution 
have to be spatially close and likely interact directly. 
The  rescue  of recognition  was  obtained  with  mono- 
(Fig.  3 A), oligo-  (Fig.  3  B)  or polyclonal (Table  1)  CTLs, 
indicating that reversion occurs for the majority ofc~OVA 
and otHSV  CTLs,  and not just for a few clones.  This was 
reminiscent of the effect of H-2K  bins on OVA presentation 
and positive selection,  which  affect the  entire  CTL reper- 
toire  (16,  17).  The  rescue  of recognition  for  long-term 
CTLs (Fig. 3) was more eflficient than for "primary" CTLs 
(Table  1),  where  2E/K  bins was  recognized  only  at  high 
peptide  concentrations  (10 -8,  as opposed to  10 -12 for wt/ 
Kb), and resulted in lower lysis levels. We explain this dis- 
crepancy by differential affinity of primary versus long-term 
Report Figure 2.  Molecular modelling of the B pocket in various peptide/MHC complexes.  The peptide is shown in cyan, the MHC in white, with oxygens 
as red and nitrogens as blue spheres. Side chains which are nmtated in K  bins are shown in magenta.  Hydrogen bonds are shown as yellow spheric dots.  (a) 
Pocket B  hydrogen bonding network  in  the  2.5  /i  crystal  structure  of OVA/K  b (11).  This  network,  formed  between E24(MHC),  Y45(MHC), 
Y22(MHC),  N70(MHC),  and the carbonyl of P5 is conserved in the crystal structure of the VSV/K  b and,  with the exception of the N70(MHC)-P5 
bond, in the structure of the SEV/K  b complex (12). (b) Predicted model of the HSV/K  b complex.  The HSV/K  b complex is likely to preserve the hydro- 
gen bonds in the t3 pocket, and P2S, relative to P2I in OVA, could provide for another hydrogen bond with E24(MHC), which is predicted to occur 
without any significant structural  rearrangements of the complex. One caveat of this model is that HSV P4E,  relative to P4N in OVA, could be a source 
of difficult to predict structural  variation.  (c) Naive model of the HSV/K  bin8 complex. The substitutions  Y22-+F and E24--+S in H-2K  bin8 are expected to 
dramatically affect the shape and chemistry of the B pocket. In the case of HSV/K  binS, with P2S and S24(MHC), the complex is unlikely to maintain the 
structure presented in Fig. 2, b and c, because a large void volume would be present in the B pocket, and only three out of six hydrogen bonds could be 
formed.  To achieve a high affinity complex, either the peptide, the MHC, or both, are probably rearranged relative to the model presented here.  Peptide 
backbone atoms of P1-P4 and MHC residues N70 and, especially, K66 (12) (which are solvent-exposed and adjacent to the peptide) are likely candidates 
for this structural  variation.  Their variation is strongly  predicted to affect TCP, recognition. (d) Predicted model of the H2E/K  bins complex.  A single 
amino acid change of P2 to E in HSV and OVA has the potential of creating H-2K  bin8 complexes which are nearly isostmctural  to that of HSV/H-2K  b 
and OVA/H-2K  b. With the exception of the lost hydroxyl group because of Y22-->F, an extended hydrogen bonding network in the B pocket, similar 
to those of Fig. 2, a and b, could be completely restored in the 2E/H-2K  bin8 complexes. 
CTLs,  the later being selected for high affinity. Among  pri- 
mary CTLs,  only the high affinity ones would interact with 
both  wt/K b  and  2E/K binS,  while  the  others  would  not. 
However,  it follows  from  the  above  discrepancy  that 2E/ 
K bins and  wt/K b  complexes  must  be  very similar,  but  not 
identical. 
Conformational  Variation Best Explains the Effects of H-2I~  ''8 
Mutation and of Second-site Revertant Peptides on T  Cell Recog- 
nition.  We  next  tested  whether  the  gain  in  recognition 
might be explained by improved binding of P2 variant pep- 
tides  to  H-2K bin8. Both  wild-type  peptides,  as  well  as  the 
conservative  substitution  O2A,  bound  strongly  to  H-2K b, 
while O2E, H2E,  and O2D  bound poorly, probably owing 
to  unfavorable  steric  and  electrostatic  interactions  of their 
acidic  P2  residues  with  MHC24E  in  the  B  pocket.  O2E 
stabilized  H-2K bin8 similarly  or  slightly  worse  than  OVA 
and  O2A  (Fig.  1  at), but  was  nevertheless  recognized  by 
OVA/H-2Kb-specific  CTLs,  while  OVA  and  O2A  were 
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H-2K  bins therefore,  may  be  explained  by  peptide:MHC 
structural  variation.  Likewise,  since  HSV  and  H2E  stabi- 
lized H-2K  bm8 equivalently (Fig.  1 b), conformational vari- 
ation most plausibly explains why only the H2E/H-2K  bin8 
complex was recognized (Table  1 and Fig. 3 B). 
The side chain of P2 is buried in the groove, is inaccessi- 
ble  to  the  TCR,  and  therefore  is  unlikely  to  influence 
TCR recognition directly (12, 25). Recognition of the 2E/ 
H-2K  t'ms complexes by H-2Kb-restricted CTLs implies that 
these complexes could assume conformations similar to that 
of the  wt  peptide/H-2K b  complexes.  Indeed,  computer 
modeling predicts that a single amino acid change of P2 to 
E  in HSV and OVA has the potential of creating H-2K  bm8 
complexes which are nearly isostructural  to that of HSV/ 
H-2K  b and  OVA/H-2K b,  owing to  the  restoration  of an 
extended hydrogen bonding network in the B pocket (Fig. 
2  d).  Thus  both  the  inability  of H-2K  bm8  to  efficiently 
present OVA and HSV peptides to H-2K  b restricted CTLs, 
and the rescue of this presentation by second-site 2E rever- 
tants,  can be explained by altered physicochemical interac- 
tions in pocket B, which in turn affect the TCR-interact- 
ing  surface  of  the  peptide:MHC  complex.  A  similar 
situation was found for the T4 phage lysozyme (23), where 
intramolecular  second-site  revertants  compensated  for the 
loss of hydrogen bonds via new hydrogen-bonding interac- 
tions.  By contrast to OVA and HSV,  VSV and SEV pep- 
tides are presented by H-2K  bin8 (17,  and R. Dyall, unpub- 
fished observation),  Since the side chains of these peptides 
do not interact with the B pocket, they may be less affected 
by hydrogen bond network changes.  Thus,  the loss of a B 
pocket  hydrogen  bond  network  would  influence  TCR 
recognition in a peptide-specific manner. 
Recent findings have indicated that the MHC class I:pep- 
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Figure 3.  Peptide/MHC  recognition by clonal and oligoclonal CTLs. 
(A) Recognition of SlCr-labeled K  b (circles) or K  bm8 (tcidngles)  target cells, 
pulse-coated with OVA (open symbols) or O2E (filled  symbols) by an OVA + 
K  b -  specific CTL clone I1 (5). (B) Recognition of HSV and H2E pep- 
tides presented by K  b and K  broS. Erector cells were a HSV +  K  b -  spe- 
cific CTL line. Symbols as in A, with HSV and H2E peptides replacing 
OVA and O2E, respectively. 
tide  interaction  is  not static.  MHC  side  chains  have been 
observed to adopt different rotamers when associated with 
different  peptides  (11,  12,  26,  27).  Peptide-associated 
changes  in  the  class  I:peptide  complex  could  also  be  de- 
tected by monoclonal antibodies  directed at different parts 
of the  oq  and  a 2 domains  (28-30),  and  some  may  have 
been  induced  by  indirect,  conforrnational  effects  (30). 
Consistent with the above reports, and the one on the role 
of conformational variation in alloreactivity (6),  our results 
make a strong case for the influence of MHC:peptide con- 
formational variation on TCR  recognition of H-2K  bin8 and 
the role of the B pocket hydrogen bonding network in it. 
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